Expression Profile of BCL-2, BCL-XL, and MCL-1 Predicts Pharmacological Response to the BCL-2 Selective Antagonist Venetoclax in Multiple Myeloma Models.
- DOI
- 10.1158/1535-7163.mct-15-0730
- Published
- 2016 May
- Container
- Molecular cancer therapeutics
- Publisher
- Not recorded
- Open access
- no
Credibility signals
limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1158/1535-7163.mct-15-0730,
title = {Expression Profile of BCL-2, BCL-XL, and MCL-1 Predicts Pharmacological Response to the BCL-2 Selective Antagonist Venetoclax in Multiple Myeloma Models.},
author = {Punnoose EA and Leverson JD and Peale F and Boghaert ER and Belmont LD and Tan N and Young A and Mitten M and Ingalla E and Darbonne WC and Oleksijew A and Tapang P and Yue P and Oeh J and Lee L and Maiga S and Fairbrother WJ and Amiot M and Souers AJ and Sampath D},
year = {2016},
journal = {Molecular cancer therapeutics},
doi = {10.1158/1535-7163.mct-15-0730},
url = {https://doi.org/10.1158/1535-7163.mct-15-0730}
}RIS
TY - JOUR TI - Expression Profile of BCL-2, BCL-XL, and MCL-1 Predicts Pharmacological Response to the BCL-2 Selective Antagonist Venetoclax in Multiple Myeloma Models. AU - Punnoose EA AU - Leverson JD AU - Peale F AU - Boghaert ER AU - Belmont LD AU - Tan N AU - Young A AU - Mitten M AU - Ingalla E AU - Darbonne WC AU - Oleksijew A AU - Tapang P AU - Yue P AU - Oeh J AU - Lee L AU - Maiga S AU - Fairbrother WJ AU - Amiot M AU - Souers AJ AU - Sampath D PY - 2016 JO - Molecular cancer therapeutics DO - 10.1158/1535-7163.mct-15-0730 UR - https://doi.org/10.1158/1535-7163.mct-15-0730 ER -
APA
EA, P., JD, L., F, P., ER, B., LD, B., N, T., A, Y., M, M., E, I., WC, D., A, O., P, T., P, Y., J, O., L, L., S, M., WJ, F., M, A., AJ, S., & D, S. (2016). Expression Profile of BCL-2, BCL-XL, and MCL-1 Predicts Pharmacological Response to the BCL-2 Selective Antagonist Venetoclax in Multiple Myeloma Models.. Molecular cancer therapeutics. https://doi.org/10.1158/1535-7163.mct-15-0730
Source records
- pubmed · retrieved 2026-09-26T07:22:45.428Z
- europe-pmc · retrieved 2026-09-26T07:22:45.444Z
- hal · retrieved 2026-09-26T07:22:45.466Z